期刊文献+

幽门螺杆菌尿素酶B亚单位在大肠杆菌中的融合表达与鉴定 被引量:2

Fusion expression and detection of ureB from Helicobacter pylori in E.coli
下载PDF
导出
摘要 目的 通过对幽门螺杆菌(Helicobacter pylori,Hipylori)尿素酶B亚单位在大肠杆菌中表达的研究,探索其免疫反应性。方法 用高保真PCR方法扩增H.pylori ureB基因,并定向克隆入pNEB193中,然后经酶切回收后插入原核表达载体pMAL-C2X进行融合表达。采用蛋白印迹法对表达产物进行鉴定。结果 特异PCR和酶切鉴定证实融合基因ureB克隆入表达载体,SDS-PAGE结果显示ureB在大肠杆菌中以融合蛋白形式MBP-ureB高效表达,约占细胞总蛋白量的26.7%。该融合蛋白可与H.pylori阳性病人血清发生特异反应。结论 成功构建了能高效表达H.pylori ureB的重组菌,为Hp基因工程疫苗的进一步研究奠定了基础。 Objective To research the expression of urease B subunit (ureB) of H. pylori and its ability to react with specific antigen. Methods The ureB gene were amplified from H. pylori by PCR and cloned directionally into vector pNEB193 .This gene was digested by using two kinds of restriction enzyme separately and cloned into the fusion expression vector pMAL-C2X,and the recombinant plasmid was then transform E. coli TB1 .The positive clones were screened by PCR and restriction enzyme digestion. The recombinant fusion protein MBP-ureB was induced to express by IPTG and was analyzed by SDS-PAGE and Western blot analysis. Results The ureB gene could be amplified from the recombinant fusion expression plasmid by PCR, and also the ureB gene fragment could be produced from these plasmids after restriction enzyme digestion. SDS-PAGE and optical density scanning indicated that the fusion protein was expressed in the recombinant vaccine strain TB1 (pMUB)as a protein with 105KD of molecular weight and was 26.7% of the total bacterial protein.The fusion protein could react with H. pylori ( + ) patient serum. Conclusions A recombinant vaccine strain expression fusion protein MBP-ureB of H. pylori was constructed and identified successfully, and this study will help to develop gene recombinant vaccine against H. pylori infection.
出处 《胃肠病学和肝病学杂志》 CAS 2003年第2期159-161,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 幽门螺杆菌 尿素酶B亚单位 大肠杆菌 免疫反应性 融合基因 克隆 幽门螺杆菌感染 Helicobacter pylori Urease subunit B gene(ureB) Fusion expression Vaccine
  • 相关文献

参考文献7

  • 1[1]de Boer W, Driessen W, Jansz A, et al. Ettect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet, 1995,345 (8953): 817-820.
  • 2[2]Lee CK, Soike K, Giannansca P, et al. Immunization of rhesus monkeys with mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. Vaccine, 1999,17 ( 23-24 ): 3072-3082.
  • 3[3]Myers GA, Ermak TH, Georgakopoulis K, et al. Oral immunization with recombinant Helicobacter pylori urease confer long-lasting immunity against Helicobacter felis infection. Vaccine, 1999,17(11-12): 1394-1403.
  • 4[4]Agens L,Valerie C and Pascale C. Shuttle cloning and nucleotide sequence of Helicobacter pylori genes responsible for urease activity. J Bacterol. 1991,173(6): 1920-1931.
  • 5[5]DiPetrillo MD,Tibbetts T,Kleanthous H,et al. Safety and immunogenicity of pho P/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine, 1999,18(5-6) :449-459.
  • 6[6]Lee MH, Roussel Y, Wilks M, et al. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine, 2001,19 ( 28-29): 3927-3935.
  • 7[7]Ferrero RL, Thiberge JM, Huerre M, et al. Recombinant antigens prepared from the turease subunits of Helicobacter spp: Evidence of protection in a mouse model of gastric infection. Infect Immun, 1994,62( 11 ) :4981-4889.

同被引文献28

  • 1江海洪,罗长坤.国产幽门螺杆菌疫苗进入Ⅰ期和Ⅱ期临床试验[J].中华医学杂志,2003,83(14):1209-1209. 被引量:11
  • 2Malfertheiner P,Megaraud F O,Nortain C,et al.European heli-cobacter pylori study group(EHPSG).Current concepts in the management of Helicobacter pylori infection--The Maasstricht 2-2000 consensus reports [J].Aliment Pharmacol Ther,2002,16(2):167-180.
  • 3Adameck R J,Pfaffenbach B,Szymanskic.Cure of H.pylori infe-ction using a 7 day triple therapy combing pantoprazole with two antibiotics [J].Helicobacter,1998,3(3):206-211.
  • 4Lind T,Van Zanten S V,Unge P,et al.Eradication of Helicobacter pylori using one -week triple therapies combing omeprazole with two antimicrobials: the MACH1 study [J].Helicobacter,1996,1(3):138-144.
  • 5Lind T,Megraud F,Unge P,et al.The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1 week triple therapies [J].Gastroenterology,1999,116(2): 248-253.
  • 6Wong B C,Xiao S D,Hu F L,et al.Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study [J].Aliment Pharmacol Ther,2000,14(2): 217-224.
  • 7Dammann H G,Folsch U R,Hahn E G,et al.Eradication of H.pylori with pantoprazole,clarithromycin,and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration [J].Helicobacter,2000,5(1): 41-51.
  • 8Bardhan K D,Dillon J,Axon A T,et al.Triple therapy for Heli-cobacter pylori eradication: a comparison of pantoprazole once versus twice daily [J].Aliment Pharmacol Ther,2000,14(1):59-67.
  • 9Gomollon F,Ducons J A,Ferrero M,et al.Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed,prospective analysis of 21 consecutive cases [J].Helicobacter,1999,4(4): 222-225.
  • 10周殿元,张万岱.关于幽门螺杆菌若干问题的意见(草案)[J].中华内科杂志,1997,36(7):438-439. 被引量:165

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部